Table 1 Oncogene addiction in various human cancers

MYC

Inactivation of MYC can result in dramatic and sustained tumor regression in various cancers

Felsher et al., Genes Cancer. (2010) [6]

cyclin D1

Cell proliferation

Lee et al., Cell Cycle. (2010) [7]

Met

The MET tyrosine kinase stimulates cell scattering, invasion, protection from apoptosis and angiogenesis

Comoglio et al., Nat Rev Drug Discov. (2008) [8]

PDGFRA amplification or mutation

Predictive biomarker of drug sensitivity

Swanton et al., Cancer Biol Ther. (2009) [9]

NF-kappaB

Acquisition of resistance to CPT

Togano et al., Biochem Biophys Res Commun. (2009) [10]

FIP1L1-PDGFRalpha

Generation sustained activation signaling to maintain a cell malignant phenotype

Jin et al., Cancer Sci. (2009) [11]

PDGF-B

PDGF-B is required to overcome cell-cell contact inhibition and to confer in vivo infiltrating potential on tumor cells

Calzolari et al., Neoplasia. (2008) [12]

EGFR amplification or mutations

Increased sensitivity to EGFR small molecule tyrosine kinase inhibitors

Rothenberg et al., Proc Natl Acad Sci USA. (2008) [13]

SphK1

SphK1 is involved in the major mechanisms underpinning oncogenesis

Vadas et al., Biochim Biophys Acta. (2008) [14]

E2F1

The E2F1 protein functions as a transcription factor that enhances cell proliferation

Alonso et al., Cancer Lett. (2008)

[15]

HSP90

Cell proliferation and/or survival

Workman et al., Ann N Y Acad Sci. (2007) [16]

Bcr-Abl

Chemosensitivity to imatinib

Chen et al., Cancer Res. (2006) [17]

mTOR

mTOR plays a central role in cell growth, proliferation and survival

Choo et al., Cancer Cell. (2006) [18]

microRNA-21

Overexpression of miR-21 leads to a pre-B malignant lymphoid-like phenotype

Medina et al., Nature. (2010) [19]